CR Bard buys majority interest in X-Trode:
This article was originally published in Clinica
CR Bard has bought a majority stake in Italian coronary stent manufacturer X-Trode. Chairman and CEO of Bard, William Longfield, says the purchase will provide Bard with a stainless steel coronary stent superior to those already on the market. Terms of the deal were not disclosed.
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.